Lajos Pusztai
Medical Oncology · New Haven, CTNPI 1437241510
Payments from drug & device makers
Across 387 payments — averaging $60,653 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$20.9M
- AstraZeneca$1.5M
- Merck$593K
- Seagen Inc.$401K
- GSK$43K
- Genentech, Inc.$26K
- plus $70K from 16 others
Across 4 payments — averaging $4370.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$15K
- Astellas Pharma Global Development$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 82 | $20,857,765 |
| AstraZeneca | 53 | $1,482,565 |
| Merck | 104 | $592,651 |
| Seagen Inc. | 61 | $401,042 |
| GSK | 19 | $42,896 |
| Genentech, Inc. | 4 | $25,556 |
| Astrazeneca UK Limited | 17 | $16,219 |
| Novartis | 7 | $15,552 |
| E.r. Squibb & Sons, L.L.C. | 7 | $7,565 |
| Gilead | 8 | $5,838 |
| Jazz Pharmaceuticals Inc. | 1 | $4,120 |
| F. Hoffmann-la Roche AG | 2 | $4,110 |
| Radius Health, Inc. | 4 | $3,089 |
| Stemline Therapeutics Inc. | 2 | $2,560 |
| Daiichi Sankyo Inc. | 1 | $2,055 |
| Beone Medicines USA, Inc. | 3 | $1,849 |
| Macrogenics, Inc. | 1 | $1,800 |
| Clovis Oncology, Inc. | 2 | $1,613 |
| Tersera Therapeutics LLC | 3 | $1,440 |
| Foundation Medicine, Inc. | 2 | $927 |
| Genentech USA, Inc. | 3 | $868 |
| Athenex Pharmaceutical Division, LLC | 1 | $500 |
How this compares
$23,472,580 in reported general payments places this provider in the 95th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New Haven
- Sarah GoldbergNew Haven$17.7M
- Harriet KlugerNew Haven$17.7M
- Daniel PetrylakNew Haven$10M
- Ian KropNew Haven$7.5M
- Anne ChiangNew Haven$5.8M
- Noffar BarNew Haven$5.4M
- Scott GettingerNew Haven$5.1M
- Jill LacyNew Haven$3.5M
- Aarti BhatiaNew Haven$3.5M
- Barbara BurtnessNew Haven$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.